Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Circulating FSTL3 and Age-related Cardiac Hypertrophy


? DESCRIPTION (provided by applicant): Understanding how juvenile protective factors can influence heart disease in the elderly is of paramount importance. We have recently demonstrated that age-related cardiac hypertrophy can be reversed by exposure to a young circulatory environment, utilizing the experimental model of parabiosis. We identified the TGF-beta family member GDF11 as a circulating hormone, with increased levels of GDF11 in the blood of young mice compared to old mice. As described in this proposal, our findings are also relevant to humans, as low serum levels of GDF11 significantly predict increased mortality over the next 8 years in patients with coronary heart disease. The effect of GDF11 is not limited to the heart, as our newly published studies show that administration of GDF11 to old mice can restore skeletal muscle function. In addition, we have now published that GDF11 can improve angiogenesis in the brains of older mice, suggesting that the loss of GDF11 in older mice is an important factor in multiple tissues. These findings reveal that restoring circulating GDF11 in old mice toward youthful levels can reverse some of the effects of aging, and thus GDF11 may represent a juvenile protective factor. It is very plausible that there is an ongoing delicate balance that must be maintained between some of the TGF-beta signaling molecules and their antagonists. Follistatin like 3 (FSTL3) is a known TGF-beta family antagonist and since it lacks a heparin-binding domain, it is particularly interesting as a potential circulating inhibitor of GDF1. Thus exploration of the dynamic interplay between GDF11 and FSTL3 in the regulation of age-induced phenotypes such as cardiac hypertrophy could reveal important insights into this age-dependent hormonal system. Here we propose that increasing levels of FSTL3 in the circulatory system of young mice, which have higher levels of GDF11, can regulate cardiac hypertrophy (Aim 1). We also propose that increased FSTL3 can inhibit the beneficial effects of exogenous GDF11 (Aim 2). The proposed experiments are highly feasible and have the potential to provide understanding of the balance of GDF11 and FSTL3 in adult mammals that is critical to consideration of GDF11 as a juvenile protective factor. Our Aims are: Aim 1: To test the hypothesis that increased circulating FSTL3 in young mice affects cardiac hypertrophy and gene expression. Aim 2: To test the hypothesis that increasing levels of circulating FSTL3 regulates the response to GDF11 in the reversal of cardiac hypertrophy of old mice.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.